Multi-marker INDex for the Risk Assessment of Sepsis in the Emergency departmenT (MINDSET) (MINDSET)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00472628|
Recruitment Status : Withdrawn (Change in company strategy)
First Posted : May 14, 2007
Last Update Posted : July 21, 2015
|Condition or disease||Intervention/treatment|
|Sepsis||Procedure: Blood samples collected|
This is a multi-center, prospective specimen procurement study. The samples will be used for future testing of the Triage Sepsis Panel in conjunction with other laboratory tests and clinical assessments as an aid in the assessment for risk of sepsis progression within 72 hours of patients presenting in the Emergency Department and meeting the diagnostic criteria for sepsis who might be considered for hospital admission, including to the ICU. Approximately 700 patients presenting to the Emergency Department (ED) with at least two of the symptoms or signs of sepsis will be enrolled in this study.
The day of enrollment is defined as Study Day 0. Enrolled patients who are discharged to home will be contacted by telephone on Study Days 3, 14 and 28 to assess their clinical status.
Patients who are admitted to the hospital following initial enrollment will undergo the following assessments at 24, 48 and 72 hours after enrollment and at discharge (if in the hospital and alive at these time points).
Each patient will also be contacted on Study Day 14 and on or after Study Day 28 to assess the duration of hospital stay and mortality through Days 14 and 28.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Multi-marker Index for the Risk Assessment of Sepsis in the Emergency Department|
|Study Start Date :||May 2007|
|Actual Study Completion Date :||August 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00472628
|Principal Investigator:||Emanuel Rivers, MD, MPH||Henry Ford Hospital|
|Principal Investigator:||Mitchell Levy, MD||Rhode Island Hospital|